Tags

Type your tag names separated by a space and hit enter

[Current pharmacotherapy of epilepsy in adults].

Abstract

The availability of new antiepileptic drugs (AEDs) has expanded the spectrum of medical treatment options in epilepsy. However, the development of ten new compounds (vigabatrin, felbamate, gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, zonisamide, and pregabalin) has not changed the basic principles of epilepsy treatment. The choice of an AED depends upon seizure type or seizure syndrome, efficacy, safety, tolerability, patient age and gender, concomitant medication, and comorbid conditions. In general, most of the newer AEDs are not necessarily more effective but usually better tolerated than the traditional agents mainly because of their favorable pharmacokinetic profiles and fewer drug interactions. Because treatment options have been widened with the introduction of these new compounds, drug therapy can now be tailored to the requirements of the individual patient. Nevertheless, significant safety and efficacy issues continue to exist and there is a strong need for the development of even better agents. This clinical review focuses on current aspects of drug therapy in epilepsy.

Authors+Show Affiliations

Département des Neurosciences, Centre Hospitalier de Luxembourg, 4, rue Barblé, L-1210 Luxembourg. beyenburg.stefan@chl.lu

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

17176542

Citation

Beyenburg, Stefan. "[Current Pharmacotherapy of Epilepsy in Adults]." Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg, 2005, pp. 263-81.
Beyenburg S. [Current pharmacotherapy of epilepsy in adults]. Bull Soc Sci Med Grand Duche Luxemb. 2005.
Beyenburg, S. (2005). [Current pharmacotherapy of epilepsy in adults]. Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg, (3), pp. 263-81.
Beyenburg S. [Current Pharmacotherapy of Epilepsy in Adults]. Bull Soc Sci Med Grand Duche Luxemb. 2005;(3)263-81. PubMed PMID: 17176542.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Current pharmacotherapy of epilepsy in adults]. A1 - Beyenburg,Stefan, PY - 2006/12/21/pubmed PY - 2007/1/24/medline PY - 2006/12/21/entrez SP - 263 EP - 81 JF - Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg JO - Bull Soc Sci Med Grand Duche Luxemb IS - 3 N2 - The availability of new antiepileptic drugs (AEDs) has expanded the spectrum of medical treatment options in epilepsy. However, the development of ten new compounds (vigabatrin, felbamate, gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam, zonisamide, and pregabalin) has not changed the basic principles of epilepsy treatment. The choice of an AED depends upon seizure type or seizure syndrome, efficacy, safety, tolerability, patient age and gender, concomitant medication, and comorbid conditions. In general, most of the newer AEDs are not necessarily more effective but usually better tolerated than the traditional agents mainly because of their favorable pharmacokinetic profiles and fewer drug interactions. Because treatment options have been widened with the introduction of these new compounds, drug therapy can now be tailored to the requirements of the individual patient. Nevertheless, significant safety and efficacy issues continue to exist and there is a strong need for the development of even better agents. This clinical review focuses on current aspects of drug therapy in epilepsy. SN - 0037-9247 UR - https://www.unboundmedicine.com/medline/citation/17176542/[Current_pharmacotherapy_of_epilepsy_in_adults]_ L2 - http://www.diseaseinfosearch.org/result/2593 DB - PRIME DP - Unbound Medicine ER -